CTOs on the Move

NeoSync

www.neosync.com

 
NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.neosync.com
  • 28 Damrell Street Loft 101
    Boston, MA USA 02127
  • Phone: 781.373.1078

Executives

Name Title Contact Details

Funding

NeoSync raised $13M on 08/10/2017

Similar Companies

Fisher and Paykel Healthcare Corporation Limited

Fisher and Paykel Healthcare Corporation Limited is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VoxelCloud

At VoxelCloud, our vision is to transform how medical practitioners work with and interpret medical images and clinical data using cloud computing and artificial intelligence, and to improve the lives of millions through accurate, accessible, and timely medical analytics.

Major's Wholesale Medical Supply

Major's Wholesale Medical Supply is a Ontario, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viz

In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.

Novadaq

Enabling surgeons with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their surgeons, while reducing health care costs, is Novadaq’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to harmful ionizing radiation or contrast dye toxicity. More than 130 peer-reviewed publications demonstrate that the use of SPY during complex surgery, leads to fewer post-operative complications and lower hospital costs. The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.